JAN 03, 2013
GlobeNewswire
NovaBay Pharmaceuticals, Inc. today announced enrollment of the first patients in India for its global phase 2b study of NVC-422 Ophthalmic Solution for adenoviral conjunctivitis.
NVC-422 is one of NovaBay's proprietary Aganocide compounds, which work by mimicking the body's natural defense against infection.
BAYnovation is a multi-centered, randomized clinical study expected to enroll approximately 450 patients with confirmed adenoviral conjunctivitis throughout the United States, India and Brazil. The study will evaluate NVC-422's efficacy in eliminating the adenoviral infection. Enrollment is now underway in both the U.S. and India and is expected to be initiated soon in Brazil. Results are expected in the second half of this year.